Publication:
A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.

Simple item page
dc.contributor.authorGarcia, J L
dc.contributor.authorLozano, R
dc.contributor.authorMisiewicz-Krzeminska, I
dc.contributor.authorFernandez-Mateos, J
dc.contributor.authorKrzeminski, P
dc.contributor.authorAlfonso, S
dc.contributor.authorMarcos, R A
dc.contributor.authorGarcia, R
dc.contributor.authorGomez-Veiga, F
dc.contributor.authorVirseda, A
dc.contributor.authorHerrero, M
dc.contributor.authorOlmos, D
dc.contributor.authorCruz-Hernandez, J J
dc.contributor.funderGerencia Regional de Salud, Junta de Castilla y León
dc.contributor.funderINNOCAMPUS Program
dc.date.accessioned2023-01-25T09:47:18Z
dc.date.available2023-01-25T09:47:18Z
dc.date.issued2017-06-09
dc.description.abstractAndrogen receptor (AR) splice variant 7 (AR-V7) has been related with both a higher risk of prostate cancer (PC) progression and differential responsiveness to hormonal agents versus chemotherapy. The objective of this study was to investigate the feasibility of a novel capillary nano-immunoassay in assessing AR-V7 in plasma from PC patients. Patients with either localized or advanced PC were included in the study. Assessment of AR-V7 in plasma was performed through a capillary nano-immunoassay platform. Correlation with clinical data, stem cell biomarkers (such as CD133+), AR amplification and PTEN status was identified. The study included 72 PC patients. AR-V7 signal was detected in 21 (29%) patients: 17 (81%) had a Gleason score ≥7, 15 (71%) castration-resistant prostate cancer (CRPC), 18 (86%) metastatic disease and PSA (median) high than AR-V7 negative (p  Assessing the presence of AR-V7 in plasma from PC patients is feasible by a novel capillary nano-immunoassay. AR-V7 was observed in 29% of the tumors and is more frequent in aggressive tumors.
dc.description.sponsorshipPartiality supported by Grant from Gerencia Regional de Salud, Junta de Castilla y León (Refs: GRS 992/A/14 y BIO/SA35/14) and INNOCAMPUS Program (CEI10-1-0010)
dc.description.versionSi
dc.identifier.citationGarcía JL, Lozano R, Misiewicz-Krzeminska I, Fernández-Mateos J, Krzeminski P, Alfonso S, et al. A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients. Clin Transl Oncol. 2017 Nov;19(11):1350-1357
dc.identifier.doi10.1007/s12094-017-1675-5
dc.identifier.essn1699-3055
dc.identifier.pmid28600675
dc.identifier.unpaywallURLhttps://digital.csic.es/bitstream/10261/169283/4/anovelpatient.pdf
dc.identifier.urihttp://hdl.handle.net/10668/11290
dc.issue.number11
dc.journal.titleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
dc.journal.titleabbreviationClin Transl Oncol
dc.language.isoen
dc.organizationInstituto de Investigación Biomédica de Málaga-IBIMA
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationHospital Universitario Regional de Málaga
dc.page.number1350-1357
dc.publisherSpringer
dc.pubmedtypeJournal Article
dc.relation.projectIDGRS992/A/14
dc.relation.projectIDBIO/SA35/14
dc.relation.projectIDCEI10-1-0010
dc.relation.publisherversionhttps://dx.doi.org/10.1007/s12094-017-1675-5
dc.rights.accessRightsRestricted access
dc.subjectAR-V7
dc.subjectAndrogen receptor
dc.subjectCD133
dc.subjectCapillary nano-immunoassay
dc.subjectCirculating tumor cells
dc.subjectPTEN
dc.subject.decsInmunoensayo
dc.subject.decsCapilares
dc.subject.decsPlasma
dc.subject.decsNeoplasias de la próstata
dc.subject.decsReceptores androgénicos
dc.subject.decsBiomarcadores
dc.subject.decsCastración
dc.subject.meshAC133 Antigen
dc.subject.meshAlternative Splicing
dc.subject.meshBiomarkers, Tumor
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshImmunoassay
dc.subject.meshMale
dc.subject.meshNanomedicine
dc.subject.meshNeoplastic Cells, Circulating
dc.subject.meshPilot Projects
dc.subject.meshPrognosis
dc.subject.meshProstatic Neoplasms
dc.subject.meshReceptors, Androgen
dc.titleA novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.
dc.typeresearch article
dc.type.hasVersionSMUR
dc.volume.number19
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format
Download

Collections

Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
SAS - Hospital Regional Universitario de Málaga
SAS - Hospital Universitario Virgen de la Victoria

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía